WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Authors
Keywords
ADAPT, Biomarker, Early breast cancer, Investigator initiated trial
Journal
Trials
Volume 14, Issue 1, Pages 261
Publisher
Springer Nature
Online
2013-08-19
DOI
10.1186/1745-6215-14-261
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer
- (2013) Philip M. Spanheimer et al. AMERICAN JOURNAL OF SURGERY
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
- (2013) Edith A. Perez et al. BREAST CANCER RESEARCH AND TREATMENT
- Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
- (2013) N. Harbeck et al. EUROPEAN JOURNAL OF CANCER
- Chemotherapy regimens in early breast cancer: major controversies and future outlook
- (2013) Markus Joerger et al. Expert Review of Anticancer Therapy
- HER2 Status by Standardized Immunohistochemistry and Silver-EnhancedIn SituHybridization in Korean Breast Cancer
- (2013) Young Kyung Bae et al. Journal of Breast Cancer
- Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review
- (2012) Asmaa Al-Allak et al. Expert Review of Anticancer Therapy
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel
- (2011) Eva J Kantelhardt et al. BMC CANCER
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
- (2011) Elisabeth Luporsi et al. BREAST CANCER RESEARCH AND TREATMENT
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
- (2011) Laura J. Esserman et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
- (2011) Manfred Schmitt et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Quality assessment of HER2 testing by monitoring of positivity rates
- (2011) Harald Choritz et al. VIRCHOWS ARCHIV
- Personalized treatment of early-stage breast cancer: Present concepts and future directions
- (2010) Nadia Harbeck et al. CANCER TREATMENT REVIEWS
- Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20
- (2010) Eleftherios P. Mamounas et al. JOURNAL OF CLINICAL ONCOLOGY
- Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
- (2010) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Jenseits von Staging, Typing und Grading
- (2009) H.H. Kreipe et al. PATHOLOGE
- Trial Assessing Individualized Options for Treatment for breast cancer: the TAILORx trial
- (2008) Jo Anne Zujewski et al. Future Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started